Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults by Osuna Prieto, Francisco J. et al.
Osuna‑Prieto et al. Cardiovasc Diabetol          (2021) 20:151  
https://doi.org/10.1186/s12933‑021‑01333‑3
ORIGINAL INVESTIGATION
Elevated plasma succinate levels are linked 
to higher cardiovascular disease risk factors 
in young adults
Francisco J. Osuna‑Prieto1,2,3† , Borja Martinez‑Tellez1,4† , Lourdes Ortiz‑Alvarez1,12 , Xinyu Di5 ,  
Lucas Jurado‑Fasoli1 , Huiwen Xu1,12 , Victoria Ceperuelo‑Mallafré6,7,8 , Catalina Núñez‑Roa6,7 ,  
Isabelle Kohler9,10 , Antonio Segura‑Carretero2,3 , José V. García‑Lario11, Angel Gil12,13,14 ,  
Concepción M. Aguilera12,13,14 , Jose M. Llamas‑Elvira15 , Patrick C. N. Rensen4 , Joan Vendrell6,7,8 , 
Jonatan R. Ruiz1*†  and Sonia Fernández‑Veledo6,7*†  
Abstract 
Background: Succinate is produced by both host and microbiota, with a key role in the interplay of immunity and 
metabolism and an emerging role as a biomarker for inflammatory and metabolic disorders in middle‑aged adults. 
The relationship between plasma succinate levels and cardiovascular disease (CVD) risk in young adults is unknown.
Methods: Cross‑sectional study in 100 (65% women) individuals aged 18–25 years from the ACTIvating Brown 
Adipose Tissue through Exercise (ACTIBATE) study cohort. CVD risk factors, body composition, dietary intake, basal 
metabolic rate, and cardiorespiratory fitness were assessed by routine methods. Plasma succinate was measured with 
an enzyme‑based assay. Brown adipose tissue (BAT) was evaluated by positron emission tomography, and circulating 
oxylipins were assessed by targeted metabolomics. Fecal microbiota composition was analyzed in a sub‑sample.
Results: Individuals with higher succinate levels had higher levels of visceral adipose tissue (VAT) mass (+ 42.5%), tri‑
glycerides (+ 63.9%), C‑reactive protein (+ 124.2%), diastolic blood pressure (+ 5.5%), and pro‑inflammatory omega‑6 
oxylipins than individuals with lower succinate levels. Succinate levels were also higher in metabolically unhealthy 
individuals than in healthy overweight/obese peers. Succinate levels were not associated with BAT volume or activity 
or with fecal microbiota composition and diversity.
Conclusions: Plasma succinate levels are linked to a specific pro‑inflammatory omega‑6 signature pattern and 
higher VAT levels, and seem to reflect the cardiovascular status of young adults.
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Background
Cardiovascular disease (CVD) remains the main cause 
of death worldwide [1]. Worryingly, the rates of CVD 
are increasing in young/middle-aged adults (18–
45 years) [2]. The incorporation of new circulating bio-
chemical markers and technologies are improving the 
detection of CVD risk in the general population [3, 4]. 
Early identification of individuals at risk of develop-
ing CVD is important [5], but predictive biomarkers 
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of CVD risk and related metabolic disturbances are 
not well characterized in young adults [6]. Advances in 
the functional analysis of the human metabolome have 
yielded many new endogenous metabolites as poten-
tial biomarkers for CVD [7], including the tricarboxylic 
acid (TCA) cycle intermediate succinate [8].
Historically considered as a respiratory substrate 
of the mitochondrial electron transport chain, suc-
cinate is now known to have additional physiological 
roles. For example, it acts as a signaling molecule in 
both intracellular and extracellular compartments by 
binding and activating its cognate receptor, succinate 
receptor 1 (SUCNR1), also known as G-protein cou-
pled receptor 91 [9]. In addition to being a marker of 
hypoxia and a driver of tissue damage [10], succinate 
is now recognized as a pro-inflammatory signal that 
boosts immune activation [11–13]. We and others have 
shown that succinate also plays a key role in the fine-
tuning of the inflammatory response, acting both as an 
alarmin [11–13] and as a resolving molecule [14–17]. 
Moreover, succinate is a positive regulator of intestinal 
gluconeogenesis [18], activates brown adipose tissue 
(BAT) thermogenesis [19], and is involved in the mus-
cle-remodeling program in response to exercise [20, 
21]. Additional roles for succinate in energy metabo-
lism are anticipated from the finding that acute dietary 
intake modulates post-prandial succinate plasma levels 
by a mechanism that is dependent on intestinal glucose 
sensing and metabolic status [22]. Succinate is also a 
microbiota-derived metabolite with a key role in gov-
erning intestinal homeostasis [23]. Succinate levels are 
clearly elevated in inflammatory-related health condi-
tions, including obesity and type 2 diabetes (T2D) [22, 
24–26], and are also related to a microbiota dysbiosis 
signature [26]. Indeed, succinate has been validated 
as a surrogate biomarker of poor metabolic control 
in patients with obesity and T2D [22, 24, 26] and can 
predict diabetes remission in patients undergoing 
bariatric surgery [24]. To date, however, no study has 
investigated whether circulating succinate levels are 
associated with CVD risk, or whether it can be a bio-
marker of CVD risk in young adults [3–6].
Oxylipins are a large family of lipid-based metabolites 
derived from polyunsaturated fatty acids that differen-
tially regulate inflammatory processes, representing a 
novel group of putative CVD risk biomarkers [27, 28]. 
Omega-3 oxylipins mainly exert anti-inflammatory and 
pro-resolving effects, whereas omega-6 oxylipins are 
mainly involved in pro-inflammatory processes [29, 
30]. Interestingly, previous work has established a link 
between higher levels of circulating omega-6 oxylipins 
and an elevated pro-inflammatory status and CVD risk 
[31, 32], but little is known about the role of omega-3 
oxylipins for CVD risk.
In the present study, we aimed to determine the rela-
tionship between plasma succinate levels and CVD risk 
in young adults. We examined whether succinate levels 
correlate with traditional and novel CVD risk factors (i.e., 
oxylipins) in a well-phenotyped cohort of young adults.
Methods
Participants
The present study was conducted within the framework 
of the ACTIvating Brown Adipose Tissue through Exer-
cise (ACTIBATE) study [33], a randomized controlled 
trial designed to determine the effect of exercise on BAT 
activity (Clinical trials identifier: NCT02365129). Inclu-
sion criteria were the following: to be sedentary (< 20 min 
moderate-to-vigorous physical activity on < 3  days/
week), non-smoker, not taking any medication, and sta-
ble body weight over the last 3 months. Exclusion criteria 
were: diagnosis of diabetes, hypertension or any medi-
cal condition(s) that can interfere with or be aggravated 
by exercise, being pregnant, using medication (includ-
ing antibiotics) that could affect energy metabolism or 
gut microbiota, and being frequently exposed to cold 
temperatures (e.g., indoors/outdoors workspace with 
low-temperatures, such as cold-storage works, ski/snow 
monitors, fieldwork during the winter sessions or low-
temperature areas). All participants gave their informed 
consent and the study was approved by the Ethics Com-
mittee on Human Research of the University of Granada 
(no. 924), and Servicio Andaluz de Salud (Centro de Gra-
nada, CEI-Granada).
We selected participants from the ACTIBATE study 
with valid data for serum CVD risk factors, body com-
position, dietary intake, basal metabolic rate (BMR), 
cardiorespiratory fitness, brown adipose tissue (BAT) 
volume and activity, and with plasma samples avail-
able for succinate measurements. This resulted in a 
cohort of 100 young adults (65 women, 35 men; age 
18–25 years) that were used in subsequent analyses. Of 
this cohort, 58 individuals had available fecal samples 
that were used in the fecal microbiota and composition 
analysis. Table  1 shows the descriptive characteristics 
of the participants as well as the plasma succinate levels 
measured at baseline.
Procedures
All data were collected at the same hour of the day, but 
on different days within a period of 3  weeks. Partici-
pants commuted to the research center by car, bus, or 
motorcycle, and all reported to have slept as usual and 
refrained from stimulant beverages and any moderate 
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physical activity in the previous 24  h, or any vigorous 
physical activity in the 48  h prior to each visit. Partici-
pants remained still (either lying down or sitting) during 
the assessments. Self-reported menstrual cycle phase of 
female participants was recorded at each visit. All data, 
material and methods are available on request. Detailed 
procedures can be found as Additional file 1. 
Table 1 Characteristics of the individuals by tertiles of plasma succinate levels
Significant P values (P < 0.05) are shown in bold
Data are presented as mean and standard deviation (SD), otherwise stated
ATPIII National Cholesterol Education Program Adult Treatment Panel III, BAT brown adipose tissue, BMI body mass index, DBP diastolic blood pressure, FMI fat mass 
index, HDL-C high density lipoprotein‑cholesterol, HOMA index homeostatic model assessment, LDL-C low density lipoprotein‑cholesterol, LMI lean mass index, SBP 
systolic blood pressure, SUV standardized uptake value, VAT visceral adipose tissue
P from one‑way analysis of variance, or from chi‑square test (categorical variables). Plasma succinate levels are computed as tertiles
*Symbols indicates significant differences between groups (P < 0.05) after Bonferroni correction for multiple comparisons








Age (years) 21.7 ± 2.3 22.6 ± 2.1 21.6 ± 1.9 0.137
Sex (n, %) 0.777
 Men 13 (38.2) 10 (30.3) 12 (36.4)
 Women 21 (61.8) 23 (69.7) 21 (64.6)
Weight status (n, %) 0.097
 Normal‑weight 23 (67.7) 19 (57.6) 15 (45.5)
 Overweight 8 (23.5) 11 (33.3) 10 (30.3)
 Obese 3 (8.8) 3 (9.1) 8 (24.2)
BMI (kg/m2) 24.2 ± 3.8 24.0 ± 3.8 26.1 ± 5.2 0.091
LMI (kg/m2) 14.8 ± 2.1 14.1 ± 2.2 15.1 ± 2.7 0.275
FMI (kg/m2) 8.1 ± 2.7 8.5 ± 2.6 9.6 ± 3.3 0.077
Body fat (%) 33.6 ± 7.4 35.8 ± 6.7 37.0 ± 8.1 0.170
VAT (g) 289* ± 146 346 ± 178 411* ± 201 0.020
Waist circumference (cm) 78.8 ± 11.9 80.9 ± 13.3 84.3 ± 14.7 0.247
Glucose (mg/dL) 86.5 ± 6.2 88.5 ± 6.5 87.3 ± 6.9 0.466
Insulin (μUI/mL) 7.4 ± 3.9 8.2 ± 3.9 9.6 ± 6.0 0.126
HOMA index 1.6 ± 1.0 1.8 ± 1.0 2.1 ± 1.6 0.152
Total cholesterol (mg/dL) 156.2 ± 25.0 162.6 ± 31 170.2 ± 34 0.230
HDL‑C (mg/dL) 51.3 ± 9.7 52.4 ± 9.5 54.2 ± 15 0.808
LDL‑C (mg/dL) 91.2 ± 23 94.3 ± 25 95.7 ± 29 0.907
Triglycerides (mg/dL) 68.2* ± 28 80.0 ± 40 111.8* ± 70 0.002
C‑reactive protein (mg/L) 1.7* ± 2.2 2.1 ± 2.1 3.8* ± 5.1 0.039
SBP (mmHg) 114.1 ± 11 116.7 ± 11 120.4 ± 12 0.082
DBP (mmHg) 68.8* ± 7.7 71.4 ± 5.5 73.7* ± 7.6 0.023
Metabolic syndrome ATPIII (n, %) 0 (0) 1 (3) 4 (12.1) 0.068
Cardiorespiratory fitness (mL/kg/min) 44.9* ± 7.3 38.8* ± 7.7 40.6 ± 6.9 0.004
BAT volume (mL) 71.3 ± 47.3 71.0 ± 68.8 64.3 ± 56.2 0.825
BAT SUVmean 4.0 ± 2.1 3.6 ± 2.0 3.8 ± 1.8 0.794
Basal metabolic rate (kcal/d) 1335 ± 570 1518 ± 896 1407 ± 198 0.534
Energy intake (kcal/d) 1904 ± 463 1769 ± 397 1950 ± 497 0.115
Energy density intake (kcal/g/d) 1.5 ± 0.4 1.5 ± 0.3 1.4 ± 0.3 0.333
Fat intake (g/d) 84.8 ± 25.9 78.3 ± 26.4 85.7 ± 23.9 0.156
Protein intake (g/d) 77.8* ± 20.2 70.2* ± 14.6 76.4 ± 21.6 0.003
Carbohydrates intake (g/d) 202.4 ± 67.0 191.1 ± 64.4 214.2 ± 73.6 0.378
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Classification of individuals into metabolic healthy 
overweight‑obese and metabolic unhealthy 
overweight‑obese groups
Individuals were categorized as metabolic healthy over-
weight/obese (MHOO; n = 27) or metabolic unhealthy 
overweight/obese (MUOO; n = 16) as described [34]. 
The MHOO group included individuals with a body 
mass index (BMI) ≥ 25  kg/m2 and without any of 
the following cardiovascular risk factors: (i) serum 
HDL-C < 40 mg/dL for men and 50 mg/dL for women; (ii) 
serum triglycerides > 150 mg/dL; (iii) systolic blood pres-
sure > 130 mmHg or diastolic blood pressure > 85 mmHg; 
or (iv) serum glucose > 100  mg/dL. The MUOO group 
included individuals with BMI ≥ 25 kg/m2 and presenting 
with at least one of the aforementioned cardiovascular 
risk factors.
Statistical analysis
Data are presented as means ± standard deviations 
(unless otherwise stated). Plasma succinate levels were 
computed as tertiles (low, intermediate or high levels) 
using the function “Visual Binning” with SPSS (SPSS v. 
22.0, IBM SPSS Statistics, IBM Corp. Armonk, NY). For 
descriptive characteristics, categorical and continuous 
variables were used according to plasma succinate lev-
els. Differences in categorical variables between groups 
were analyzed by chi-square tests, whereas differences 
in continuous variables between groups were analyzed 
by one-way analyses of variance. The level of signifi-
cance between groups was set at P < 0.05, after Bonfer-
roni correction for multiple comparisons. Serum levels 
of cardiovascular risk parameters and plasma omega-3 
and omega-6 oxylipins levels were log10 transformed 
to achieve a normal distribution. Plasma succinate lev-
els followed a normal distribution and were not trans-
formed. The plasma succinate fold-change value was 
used to perform interaction network pathway analyses 
of plasma omega-3 and omega-6 oxylipins, computed as 
the ratio of the mean values of the two compared groups 
(i.e., high vs. low fold change = average succinate levels 
(high tertile)/average succinate levels (low tertile). Fold-
change differences were analyzed with an unpaired t-test. 
The sex distribution in the classification of MHOO and 
MUOO individuals was not similar; therefore, to study 
whether plasma succinate levels were different between 
groups the analyses were adjusted by sex as a covariate. 
No sex interaction was detected in the other analyses 
(all P > 0.05). Figure 3 and Additional file 6: Fig. S1 were 
built using GraphPad Prism version 8.0.0 for Windows 
(GraphPad Software, San Diego, CA). Figure 2 was built 
using Cytoscape software version 3.7.0 for Windows 
(Boston, MA) [35].
Results
The characteristics of the participants included in the 
study are shown in Table 1. We found a great variability 
in plasma succinate levels in the cohort (11.6–129.8 µM; 
amplitude range, 118.2  µM) (Additional file  6: Fig. S1). 
Given this broad range, we used the low (11.6–55.1 µM), 
intermediate (55.2–71.4 µM), and high (71.5–129.8 µM) 
plasma succinate tertiles for subsequent analyses 
(Table 1).
Young adults with higher plasma succinate levels have 
higher visceral adiposity and an adverse cardiovascular 
profile
Participants in the highest tertile of succinate had sig-
nificantly higher visceral adipose tissue (VAT) mass 
(+ 42.5%), serum triglyceride levels (+ 63.9%), serum 
C-reactive protein levels (+ 124.2%), and diastolic 
blood pressure (+ 5.5%) than peers in the lowest ter-
tile (Table  1). By contrast, cardiorespiratory fitness lev-
els were significantly higher in the lowest tertile (up to 
+ 15.7%) than in the intermediate tertile (Table  1). No 
significant differences were found in dietary energy and 
macronutrients intake, dietary energy density parame-
ters, BMR levels or BAT parameters across the three ter-
tiles (Table 1).
Plasma succinate levels are not associated with fecal 
microbiota composition and diversity
Analysis of the fecal microbiota in young adults revealed 
no association between succinate levels and beta or alpha 
diversity (all P ≥ 0.380 Fig.  1a, b). Similarly, no associa-
tions were found between succinate levels and relative 
abundances at the phylum level (all P > 0.05; Fig. 1c, left 
panel). Nonetheless, we found that individuals in the 
lowest tertile of plasma succinate had a higher relative 
abundance of Bacteroides (+ 56.9%) and a lower relative 
abundance of Acidaminococcus (− 93.8%) than individu-
als in the intermediate and highest tertiles, respectively 
(all P ≤ 0.01; Fig.  1c, right panel). No significant differ-
ences were observed in the relative abundance of the 
species belonging to Bacteroides and Acidaminococcus 
genera across the succinate tertiles (all P > 0.05; Addi-
tional file  3: Table  S2). Likewise, no associations were 
found between succinate levels and succinate-producing 
or succinate-consuming species (all P > 0.05; Additional 
file 4: Table S3 and Additional file 7: Fig. S2a, b).
Plasma succinate levels are associated 
with pro‑inflammatory omega‑6 oxylipins
Given the clear link between plasma succinate and some 
pro-inflammatory markers, such as serum C-reactive 
protein and serum triglycerides (Table  1) [36], and the 
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Fig. 1 Fecal microbiota diversity and composition by tertiles of plasma succinate (n = 58). L: Low succinate plasma concentration (11.6–57.3 µM); 
I: Intermediate succinate plasma concentration (57.3–75.3 µM); H: High succinate plasma concentration (75.4–129.8 µM). A Principal Coordinate 
Analysis (PCoA) plot of the first two principal coordinates at phylum and genus level, categorized by circulating succinate levels. Genus PCoA 
only shows PCoA analyses done using Bray–Curtis dissimilarity. Ellipses represent the 95% confidence intervals (package, vegan, R version 3.6). 
B Differences between the circulating succinate tertiles in fecal microbiota diversity indexes (richness Chao, Shannon, inverse of Simpson, and 
evenness Camargo). Kruskal–Wallis test (P < 0.05) was used to test for each pairwise comparison. C Relative abundance of the fecal microbiota at 
phylum (left panel) and genus level (right panel) according to circulating succinate levels. Stacked bar represented percentage abundance. The 
symbol (asterisk) means statistical significance differences between Low and Intermediate levels, whereas the symbol (filled circle) means statistical 
significance differences between low and high levels, determined by Kruskal–Wallis test, corrected for multiple comparisons FDR (P < 0.05)
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lack of associations between plasma succinate levels 
and classical inflammatory markers (i.e., IL-6, TNF-α or 
IFN-γ; data not shown), we extended our investigation 
to the fatty acid-derived oxylipins. No significant differ-
ences were observed in plasma omega-3 oxylipins when 
comparing the high versus low succinate tertiles (Fig. 2a) 
(abbreviations are detailed in Additional file 2: Table S1). 
However, individuals in the highest succinate tertile had 
significantly higher plasma concentrations of omega-6 
oxylipins than individuals in the lowest tertile, includ-
ing the omega-6 fatty acids DGLA (+ 61.1%), AdrA 
(+ 47.4%) and AA (+ 28.7%), as well as several of their 
downstream products, as revealed by interaction net-
work pathway analysis (Fig. 2b). In addition, individuals 
in the highest succinate tertile had significantly lower 
levels of the omega-6 oxylipins 12,13-EpOME (− 30.7%) 
and 1a,1b-dihomo  PGF2alpha (− 25.4%). With respect to 
DGLA metabolism, the hydroxy-trienoic acid product 
resulting from 15-lipoxygenation of DGLA (15-HETrE), 
was found to be significantly higher in concentration in 
individuals in the highest succinate tertile than in those 
in the lowest succinate tertile (+ 21.8%). The concen-
tration of other downstream AA-derived oxylipins was 
also significantly higher in individuals in the highest ter-
tile of plasma succinate, including 11-HETE (+ 20.4%), 
High vs. Low succinate levels








Fig. 2 Interaction network pathway analysis of circulating omega‑3 and omega‑6 oxylipins (n = 98). The networks depict the differences of each 
lipid mediator between high versus low tertiles of plasma succinate levels. Compounds that were not detected (ND) or not measured (NM) with 
the LC–MS/MS method are shown without boxes. Blue boxes with yellow borderlines indicate that this lipid mediator was higher in high versus 
the low succinate group, whereas red boxes with yellow borderlines indicate that this lipid mediator was lower in the comparison. Boxes without 
yellow borderlines indicate that this lipid mediator did not significantly change in the comparison. Fold‑change values are depicted according to 
the legend bar on the right side. Intermediate enzymes are represented in green, and they were not measured. Comparisons are performed with 
independent t‑test analysis (log10 transformed values) and P < 0.05
Fig. 3 Comparisons between plasma succinate levels in metabolic 
healthy overweight/obese (MHOO, n = 27) and metabolic unhealthy 
overweight/obese (MUOO, n = 16) young adults. P value obtained 
from one‑way analysis of variance adjusted for sex
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12-HETE (+ 74.9%), 12-HHTrE (+ 97.9%) and TxB2 
(+ 84.8%). Only small differences in oxylipin levels were 
observed when comparing high versus medium succi-
nate tertiles (Additional file 8: Fig. S3A), but the differ-
ences observed between medium versus low succinate 
tertiles (Additional file 8: Fig. S3B) resembled the differ-
ences between high and low succinate tertiles.
Young adults with metabolically unhealthy overweight/
obesity have higher plasma succinate levels than their 
metabolically healthy counterparts
To gain more insight into the potential role of plasma 
succinate as an early marker of cardiovascular risk, we 
subcategorized the overweight/obese individuals of 
the cohort (43% of our population) as healthy (MHOO; 
n = 27) or unhealthy (MUOO; n = 16) based on their car-
diovascular profile. Individuals in the MUOO group had 
higher BMI (+ 7.2%), FMI (+ 3.1%), VAT mass (+ 24.3%), 
fasting glucose (+ 7.6%), insulin (+ 57.9%), homeostatic 
model assessment index (+ 71.5%), total cholesterol 
(+ 15.4%), triglycerides (+ 119.8%), and systolic (+ 8.2%) 
and diastolic (+ 10.1%) blood pressure than peers in the 
MHOO group, and had lower HDL-C levels (− 16.1%) 
(Additional file 5: Table S4). Moreover, plasma succinate 
levels were significantly higher (+ 21.3%) in the MUOO 
group (75.5 ± 12.3  µM) than in the MHOO group 
(62.3 ± 17.4 µM) (P = 0.009; Fig. 3).
Discussion
Here, we demonstrate for the first time to our knowl-
edge that plasma succinate is associated with VAT mass, 
serum triglycerides and C-reactive protein levels, and 
diastolic blood pressure in young adults. Likewise, indi-
viduals with higher levels of plasma succinate have higher 
levels of plasma omega-6 oxylipins, which are linked to 
increased pro-inflammatory status and, accordingly, ele-
vated CVD risk [31, 32]. By contrast, plasma succinate 
levels are not associated with BAT or with fecal micro-
biota composition and diversity. Interestingly, individuals 
who are metabolically unhealthy with overweight/obe-
sity have higher plasma succinate levels than their meta-
bolically healthy counterparts. Collectively, our findings 
suggest that plasma succinate is candidate biomarker of 
cardiovascular risk in young adults. Further studies are, 
nevertheless, needed to unravel the underlying mecha-
nisms that may explain these associations.
Investigations of the association of plasma succinate 
levels with body composition are scarce. We recently 
showed that plasma succinate levels are positively asso-
ciated with BMI in middle-aged and elderly adults with 
obesity and T2D [24, 26]. In the present study, we found 
that young adults with higher succinate levels have 
higher VAT mass, an established marker of elevated 
CVD risk [37–39]. Visceral fat depots are linked to 
metabolic dysfunction through increased mitochon-
drial oxidative stress, a main driver of cellular insulin 
resistance [40]. Interestingly, succinate dehydrogenase 
(SDH) activity is a potential source of reactive oxygen 
species (ROS) under specific conditions, including obe-
sity [41–43], suggesting an adverse influence of SDH in 
obesity. In this context, some of the metabolic improve-
ments observed after bariatric surgery are, in part, due 
to the restoration of SDH activity in VAT, which con-
curs with the weight loss caused by the surgery [44]. It is 
thus reasonable to propose that a fraction of the plasma 
succinate could originate in (and be secreted from) VAT 
depots, through SDH activity, contributing to the posi-
tive association between plasma succinate levels and 
VAT mass.
The gut microbiota plays a key role in regulating host 
metabolism, and specific signatures of gut microbiota 
composition have been associated with obesity, insulin 
resistance, and T2D [45]. Succinate is a primary cross-
feeding metabolite between gut-resident microbes, 
which is important to preserve a healthy gut microbiota 
[23]. We recently demonstrated in middle-aged adults 
that the fecal microbiota is a putative contributor of cir-
culating succinate levels in some health conditions such 
as obesity [26]. Our previous data also support the notion 
that succinate is a marker of microbiota dysbiosis, as 
intestinal permeability positively correlates with circulat-
ing succinate in individuals with obesity [26]. Nonethe-
less, we found no association between plasma succinate 
and succinate-producing or succinate-consuming bacte-
ria species in the present analysis. Differences in the age 
and metabolic status of the cohorts, or even the moder-
ate sample size of the present study (n = 100), may partly 
explain these findings.
We previously showed that circulating succinate 
is regulated nutritionally [22], and it is known that 
SUCNR1 has an intracellular anti-lipolytic function 
[46, 47]. Studies in mice have recently demonstrated 
that succinate uptake stimulates uncoupling protein 1 
(UCP1)-dependent thermogenesis in brown adipocytes 
via ROS production, protecting against diet-induced 
[19]. Our present study, however, failed to show a sig-
nificant association between systemic succinate and 
BAT volume or activity. Given the cross-sectional 
nature of our study, we cannot draw conclusions on a 
potential role of succinate in human BAT thermogen-
esis. Additionally, neither plasma succinate levels nor 
BMR were associated with parameters of energy intake/
consumption in our young cohort. Nonetheless, plasma 
succinate levels were inversely associated with cardi-
orespiratory fitness. In this line, succinate has recently 
emerged as an important player in muscle adaptation in 
Page 8 of 10Osuna‑Prieto et al. Cardiovasc Diabetol          (2021) 20:151 
response to exercise [20, 48]. While the observational 
design of our present study does not enable us to infer 
causality, it adds to the increasing body of evidence on 
the role of succinate as a possible mediator of the cardi-
ovascular benefits of exercise. Cardiorespiratory fitness 
is also recognized as a relevant risk factor associated 
with adverse cardiovascular health and poor progno-
sis [49], and a lower prevalence of metabolic syndrome 
has been reported in people with better cardiorespira-
tory fitness [50]. This may fit with our finding that the 
MUOO group had significantly higher succinate levels 
than the MHOO group, which also supports previous 
data showing higher succinate levels in obese individu-
als with T2D than in their healthy obese counterparts 
[26]. Altogether, these results strengthen the hypoth-
esis that high plasma succinate levels are linked to an 
impaired metabolic status.
Young adults with high plasma succinate levels also 
had higher plasma levels of C-reactive protein and pro-
inflammatory oxylipins. Omega-6 oxylipins are key 
metabolites in pro-inflammatory processes and are 
closely linked to the progression of obesity and to car-
diovascular risk [31, 32], whereas omega-3 oxylipins 
usually have opposing effects [31, 32]. Individuals with 
high succinate levels had higher circulating AA, a piv-
otal fatty acid precursor in a plethora of inflammatory 
processes [51], in addition to several AA downstream 
metabolites involved in pro-inflammatory processes 
[52, 53]. Specifically, we observed that circulating suc-
cinate levels were related to the omega-6 oxylipins 
11-HETE, 12-HETE, 12-HHTrE, and 15-HETrE. Pre-
vious research has linked 5-HETE and 11-HETE to 
obesity [54–56], whereas the auto-oxidative product 
15-HETrE has been associated with a high risk of car-
diovascular events [57]. Of particular note is the high 
level of TxB2 in individuals with high succinate, which 
is reported to increase in patients with coronary ather-
osclerosis [58]. In addition to an increase in AA prod-
ucts in individuals with high succinate levels, we also 
observed an increase in the precursor DGLA, which 
has been previously associated with obesity and insu-
lin resistance [59]. Likewise, the AA metabolic prod-
uct AdrA, which was higher among participants in the 
highest succinate tertile, has been shown to be directly 
associated with the risk of all-cause mortality [60]. As 
many of the enzymes (i.e., cyclooxygenases and lipoxy-
genases) involved in oxylipin metabolism are shared by 
both omega-3 and omega-6 oxylipins [61], it is not sur-
prising to find an asymmetric pattern in the omega-3 
and omega-6 oxylipins profile in the high versus low 
succinate groups.
Strengths and limitations
A major strength of the present study is the well-character-
ized population, including detailed measurements of body 
composition, BAT, and novel markers of the cardiometabolic 
profile such as oxylipins, which allow us to gain new insight 
into the inflammatory status of the individuals compared 
with classical inflammatory markers (i.e., IL-6, TNF-α or 
IFN-γ). A major limitation of the study is its cross-sectional 
design, and no causality can be established. Another limi-
tation is the limited sample size for multivariate statistical 
analyses. Finally, although 18F-FDG uptake is the current 
gold-standard for BAT quantification, it also has limitations 
in the assessment of BAT metabolic activity and volume [62].
Conclusion
Our study reveals that plasma succinate levels are linked to 
a specific pro-inflammatory omega-6 signature pattern and 
higher VAT levels, and might be useful as a novel clinical tool 
to identify young individuals at higher CVD risk, allowing 
the implementation of effective preventive treatment. Plasma 
levels of succinate seem to reflect the cardiovascular status of 
young adults, supporting its potential as a biomarker of CVD 
risk. Prospective studies are needed to confirm its clinical 
relevance and predictive value as a CVD risk biomarker.
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